Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is a global oncology research organisation founded in 1993 that runs a community-based clinical trial model, placing investigational cancer therapies in local communities rather than restricting access to major academic medical centres. The institute works with pharmaceutical and biotechnology companies on drug development programmes spanning first-in-human studies through Phase 4 trials. Its network of 1,300 or more research physicians operates across more than 200 locations in 20 American states, reaching an estimated one in five cancer patients in the communities it serves.

SCRI's work is organised around three functions. Its Site Management Organisation delivers centralised clinical trial support across the community site network. An oncology-focused Contract Research Organisation provides research services to industry partners. Personalised Medicine initiatives use genomic testing to identify and enrol patients in trials more quickly. The institute reports that it supported the majority of new cancer therapies approved by America's Food and Drug Administration over the past decade.

Technical areas covered include oncology clinical research, clinical trials, personalised medicine, genomic testing and drug development. The organisation describes its priorities as patient access and equity, innovation in how trials are delivered, and collaboration with pharmaceutical and biotech partners to accelerate the development of new cancer treatments internationally.